BioNTech's COVID vaccine sales are poised to slip, but the shot will remain a 'cash cow' in the long term: analysts

Reports of dwindling COVID-19 vaccine demand have been circulating for months. Now, the slump threatens to cut into BioNTech's revenue hauls in 2022 and beyond, according to one group of analysts.

Since much of the world has “decided to live with the virus," ODDO BHF analysts slashed their forecasts for BioNTech’s 2022 and 2023 COVID vaccine sales by 28% and 33%, respectively. This year, the team expects BioNTech to record Comirnaty sales of 14.1 billion euros, which is "at the low end" of the company's guidance of 13 billion euros to 17 billion euros, the team noted.